Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUKELSO vs AMBISOME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Advanced renal cell carcinoma,Progressive neuroendocrine tumors of pancreatic origin,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis,Advanced neuroendocrine tumors of gastrointestinal or lung origin
Empirical therapy for presumed fungal infection in febrile neutropenic patients,Treatment of cryptococcal meningitis in HIV-infected patients,Treatment of visceral leishmaniasis,Treatment of invasive aspergillosis (alternate therapy),Treatment of candidiasis (invasive and mucosal),Treatment of histoplasmosis (severe disseminated),Treatment of blastomycosis (severe),Treatment of coccidioidomycosis (severe),Treatment of mucormycosis,Treatment of fusariosis,Treatment of talaromycosis (penicilliosis)
400 mg orally twice daily with food.
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Primarily metabolized by CYP3A4
Amphotericin B is predominantly cleared via the reticuloendothelial system and is excreted slowly in urine and feces. Metabolism is not well characterized, but it is not extensively metabolized by liver enzymes.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
High protein binding, approximately 99.8%, primarily to albumin and alpha-1-acid glycoprotein.
Highly bound (>90%), primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution ~0.15 L/kg (range 0.12–0.18 L/kg), indicating limited extravascular distribution, predominantly confined to plasma and extracellular fluid.
Vd: 0.4–0.6 L/kg; reflects extensive tissue distribution, particularly into organs of the reticuloendothelial system (liver, spleen).
Oral bioavailability ~85%; unaffected by food.
Intravenous: 100% (only route of administration).
GFR ≥60 m L/min: no adjustment; GFR 30-59 m L/min: 200 mg twice daily; GFR <30 m L/min: 200 mg once daily; hemodialysis: 200 mg three times weekly after dialysis.
No dose adjustment required for renal impairment; use caution in patients with pre-existing renal disease and monitor renal function.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg twice daily; Child-Pugh C: 200 mg once daily.
No specific dose adjustment for Child-Pugh class A or B; for Child-Pugh class C, consider dose reduction or increased monitoring due to potential hepatotoxicity.
Body weight 10-20 kg: 200 mg twice daily; 20-40 kg: 300 mg twice daily; ≥40 kg: 400 mg twice daily.
For systemic fungal infections: 3-5 mg/kg/day IV; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21; weight-based dosing with no maximum daily dose specified.
No specific dose adjustment based on age alone; monitor renal function and adjust per renal guidelines.
No specific dose adjustment; monitor renal function closely due to age-related decreased GFR and potential nephrotoxicity.
No FDA black box warning.
Amphotericin B products should be used primarily for treatment of severe fungal infections in immunocompromised patients where significant toxicity is justified. Amphotericin B is associated with severe nephrotoxicity, especially when used at higher doses or with other nephrotoxic agents. Infusion-related reactions (fever, chills, rigors, hypotension) are common and may be severe.
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions,Renal impairment,Metabolic effects (hyperglycemia, hyperlipidemia),Interstitial lung disease,Hemorrhagic events,Wound healing complications,Immunosuppression,Increased risk of thrombosis
Nephrotoxicity: Monitor renal function closely; avoid concomitant nephrotoxic drugs when possible.,Infusion reactions: Premedication (e.g., acetaminophen, antihistamines, corticosteroids) may reduce severity.,Electrolyte disturbances: Hypokalemia, hypomagnesemia may occur; monitor and replace as needed.,Hepatotoxicity: Monitor liver function tests.,Cardiotoxicity: Rarely associated with arrhythmias; caution in patients with cardiac disease.,Pancreatitis: Has been reported; consider in patients with abdominal pain.
Hypersensitivity to everolimus or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation (unless the condition is life-threatening and amenable only to amphotericin B therapy)
Avoid grapefruit and grapefruit juice; may increase drug levels. Take with or without food, but high-fat meals may increase absorption. Avoid alcohol due to hepatotoxicity risk.
No known significant food interactions. Grapefruit juice does not affect liposomal amphotericin B metabolism.
First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and third trimesters: Use only if maternal benefit outweighs fetal risk; may cause fetal growth restriction or oligohydramnios in off-label experience. No adequate human data.
Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no known fetal risks.
No human data on milk excretion or infant effects. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., immunosuppression), advise against breastfeeding during treatment and for 2 weeks after last dose.
Excretion in human milk unknown; caution advised. M/P ratio not available.
No established dose adjustment in pregnancy. Consider reduced dosing if increased clearance occurs (second trimester). Monitor drug levels if available; otherwise, adjust based on clinical response and toxicity.
No dose adjustment required for systemic exposure in pregnancy; pharmacokinetic changes not significant.
Monitor for QT prolongation, electrolyte abnormalities, and hepatotoxicity. Adjust dose in renal impairment (Cr Cl <30 m L/min). Avoid use with strong CYP3A4 inhibitors or inducers. Note potential for phototoxicity; advise sun avoidance.
Am Bisome (liposomal amphotericin B) is preferred over conventional amphotericin B due to reduced nephrotoxicity and infusion-related reactions. Dose adjustment not required in renal impairment, but monitor renal function closely. Premedication with acetaminophen, diphenhydramine, and hydrocortisone may reduce infusion reactions. For cryptococcal meningitis in HIV, combination with flucytosine is recommended. Not interchangeable with other amphotericin B formulations; verify dose and product before administration.
Take exactly as prescribed; do not change dose or stop without consulting doctor.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during therapy and for 1 month after last dose.,Report symptoms like irregular heartbeat, fainting, severe nausea/vomiting, or yellowing of skin/eyes immediately.,Use sunscreen and protective clothing; avoid sun exposure, even through glass.
Take exactly as prescribed; do not skip doses or stop early.,Infusion reactions (fever, chills, nausea) may occur; report these to your healthcare provider.,Drink plenty of fluids unless advised otherwise by your doctor.,Contact your doctor immediately if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Tell your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements.,This medication can cause kidney problems; you will need regular blood tests.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUKELSO vs AMBISOME, answered by our medical review team.
AUKELSO is a Topical Antifungal that works by Selective inhibitor of the mammalian target of rapamycin (m TOR) kinase, specifically the m TORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.. AMBISOME is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUKELSO and AMBISOME depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUKELSO is: 400 mg orally twice daily with food.. The standard adult dose of AMBISOME is: 3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUKELSO and AMBISOME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUKELSO is classified as Category C. First trimester: Avoid use due to potential for fetal harm based on animal studies showing developmental toxicity (including cardiovascular and skeletal malformations). Second and . AMBISOME is classified as Category C. Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.